Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

ReNeuron wins £1.5mln to fund further development of its hRPC cell therapy candidate

ReNeuron’s human retinal progenitor cell (hRPC) therapy is being developed as a treatment for blindness-causing eye diseases such as retinitis pigmentosa
human eye
Innovate UK has backed ReNeuron and its partners in the past

Cell-based therapeutics specialist ReNeuron Group Plc (LON:RENE) has won a £1.5mln grant to further develop its human retinal progenitor cell (hRPC) therapy which is used to treat blindness-causing, degenerative eye diseases.

The grant has been awarded by Innovate UK, the UK’s innovation agency, which has backed ReNeuron and its partners before.

READ: ReNeuron making good progress with all key therapeutics programmes

This time the money will co-fund a collaborative programme of work by ReNeuron, the Cell & Gene Therapy Catapult, Roslin Cell Therapies and University College London.

They will work together to advance the development of the hRPC cell therapy candidate, which is currently in a phase I/II clinical trial in the US, in patients suffering from retinitis pigmentosa.

“We and our collaborators are delighted to have won this latest grant from Innovate UK to develop a suite of robust and reliable release and characterisation assays reflecting the mechanism of action of our hRPC cell therapy candidate,” said ReNeuron’s Sharon Grimster.

“This is a challenging but vital part of the broader commercial manufacturing strategy for the therapy and we are pleased to be working with leading academic and commercial manufacturing partners on this important programme of work.”

View full RENE profile View Profile

ReNeuron Group Plc Timeline

Related Articles

Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said
Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use